Is Pfizer Stock a Buy After This $1.25 Billion Investment?
Pfizer (NYSE: PFE) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.However, the pandemic receded, and revenue in this area dropped off a cliff. The drugmaker has been looking for a way back ever since -- a product, or several, that can rack up billions in annual sales and help its top line move consistently in the right direction.It recently found a candidate for that position. Let's look deeper, and discuss whether the recent development makes Pfizer stock a buy.Continue reading
Pfizer (NYSE: PFE) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.
However, the pandemic receded, and revenue in this area dropped off a cliff. The drugmaker has been looking for a way back ever since -- a product, or several, that can rack up billions in annual sales and help its top line move consistently in the right direction.
It recently found a candidate for that position. Let's look deeper, and discuss whether the recent development makes Pfizer stock a buy.
